Inactive Instrument

Karo Pharma AB (publ)

Equities

KARO

SE0007464888

Pharmaceuticals

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Karo Healthcare AB acquired Rights to the OTC brand Proctosedyl from Bayer Aktiengesellschaft. CI
Karo Healthcare AB acquired Topical Lamisil Business from Haleon UK Holdings Ltd. CI
Karo Healthcare AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Karo Healthcare AB agreed to acquire Topical Lamisil Business from Haleon UK Holdings Ltd. for approximately £240 million. CI
Karo Healthcare Announces Management Appointments CI
Karo Healthcare Limited Appoints Michael Kaltenborn as Chief Strategy Corporate Development Officer, Effective February 1, 2023 CI
Karo Pharma AB agreed to acquire of Six brands of Teva for DKK 84 million. CI
Karo Intressenter AB completed the acquisition of remaining 13.6% stake in Karo Pharma AB (OM : KARO). CI
EQT's Karo Intressenter Gains Control Of 97% Stake In Karo Pharma MT
Karo Pharma Gets Approval to Delist from Nasdaq First North Growth Market MT
Karo Pharma Files for Delisting from Nasdaq First North Growth Market MT
Karo Pharma Suitor Karo Intressenter Further Extends Takeover Acceptance Period MT
EQT-backed Karo Intressenter Starts Mandatory Redemption of Remaining Karo Pharma Shares MT
Karo Pharma AB(OM:KARO) dropped from S&P Global BMI Index CI
EQT-backed Karo Intressenter's $1.5 Billion Karo Pharma Takeover Becomes Unconditional MT
Karo Pharma Receives Fairness Opinion From Nordea Bank Regarding EQT-controlled Karo Intressenter's Offer MT
Karo Pharma Lands $1.6 Billion Takeover Offer From EQT-controlled Shareholder MT
Karo Intressenter AB made a public cash offer to acquire remaining 13.6% stake in Karo Pharma AB (OM : KARO) for SEK 2.2 billion. CI
Karo Pharma AB Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Karo Pharma to Raise $262 Million in Rights Issue MT
Reckitt Completes Sale of E45 Brand to Karo Pharma MT
Karo Pharma AB (OM:KARO) completed the acquisition of E45 brand and related sub-brands from Reckitt Benckiser Group plc. CI
Karo Pharma AB (OM:KARO) acquired Del Decus Enterprises Ltd. CI
Karo Pharma AB(OM:KARO) dropped from OMX Nordic All-Share Index CI
Karo Pharma Receives Approvals For $265 Million Rights Issue, Change Of Listing To Nasdaq First North Growth Market MT
Chart Karo Pharma AB (publ)
More charts
Karo Pharma AB, formerly known as Karo Bio AB, is a Sweden-based biopharmaceutical company engaged in the research and development of drugs based on the nuclear receptors. The Company's pipeline comprises three projects: Estrogen Receptor Beta (ERbeta) cancer, a platform, which focuses on the development of ERbeta in cancer treatment; ERbeta multiple sclerosis (MS), which specializes in the autoimmune disease MS treatment; and Related Orphan Receptor Gamma (RORgamma), which is responsible for the nuclear receptors application in treatment of autoimmune disease, such as rheumatoid arthritis and psoriasis. The Company collaborates with Pfizer, 4D Science, and Merck, among others. Its trademarks portfolio includes Karo Bio, BioKey, BioKey Assay and Molecular Braille. The Company operates Karo Bio Research AB, Karo Bio Discovery AB, Kommanditbolaget Odenplan Fastigheter, Tanomed AB, MedCore AB and Medireduce AB as subsidiaries.
More about the company